Literature DB >> 25034103

The RalGEF/Ral pathway: evaluating an intervention opportunity for Ras cancers.

Jonathan M Cooper1, Brian O Bodemann1, Michael A White2.   

Abstract

Recognition that Ral guanine nucleotide exchange factors (RalGEFs) are direct Ras effectors and that Ral G-protein activation is a direct consequence of Ras activation has spurred focused efforts to establish the contribution of RalGEF/Ral signaling to oncogenic transformation. Here, we provide a broad-strokes overview of the mechanistic organization of the RalGEF/Ral signaling network, evaluate the evidence for participation of this network in tumorigenic regulatory milieus, consider targeting strategies, and discuss the challenges to and opportunities for clinical development of these targeting strategies.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Exo84; Exocyst; K-Ras; RALBP1; RalA; RalB; Sec5; TBK1; ULK1; mTORC1

Mesh:

Substances:

Year:  2013        PMID: 25034103     DOI: 10.1016/B978-0-12-420146-0.00006-8

Source DB:  PubMed          Journal:  Enzymes        ISSN: 1874-6047


  7 in total

1.  Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.

Authors:  Kathleen F Ludwig; Wenting Du; Noah B Sorrelle; Katarzyna Wnuk-Lipinska; Mary Topalovski; Jason E Toombs; Victoria H Cruz; Shinichi Yabuuchi; N V Rajeshkumar; Anirban Maitra; James B Lorens; Rolf A Brekken
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

2.  Bi-allelic Variants in RALGAPA1 Cause Profound Neurodevelopmental Disability, Muscular Hypotonia, Infantile Spasms, and Feeding Abnormalities.

Authors:  Matias Wagner; Yuliya Skorobogatko; Ben Pode-Shakked; Cynthia M Powell; Bader Alhaddad; Annette Seibt; Ortal Barel; Gali Heimer; Chen Hoffmann; Laurie A Demmer; Yezmin Perilla-Young; Marc Remke; Dagmar Wieczorek; Tharsini Navaratnarajah; Peter Lichtner; Dirk Klee; Hanan E Shamseldin; Fuad Al Mutairi; Ertan Mayatepek; Tim Strom; Thomas Meitinger; Fowzan S Alkuraya; Yair Anikster; Alan R Saltiel; Felix Distelmaier
Journal:  Am J Hum Genet       Date:  2020-01-30       Impact factor: 11.025

Review 3.  Ras Multimers on the Membrane: Many Ways for a Heart-to-Heart Conversation.

Authors:  E Sila Ozdemir; Anna M Koester; Xiaolin Nan
Journal:  Genes (Basel)       Date:  2022-01-25       Impact factor: 4.096

4.  Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.

Authors:  Lu Tian; Luqing Zhao; Karen Man-Fong Sze; Charles Shing Kam; Vanessa Sheung-In Ming; Xia Wang; Vanilla Xin Zhang; Daniel Wai-Hung Ho; Tan-To Cheung; Lo-Kong Chan; Irene Oi-Lin Ng
Journal:  Hepatology       Date:  2021-12-17       Impact factor: 17.298

5.  K-ras-ERK1/2 down-regulates H2A.XY142ph through WSTF to promote the progress of gastric cancer.

Authors:  Chao Dong; Jing Sun; Sha Ma; Guoying Zhang
Journal:  BMC Cancer       Date:  2019-05-31       Impact factor: 4.638

6.  K-Ras-ERK1/2 accelerates lung cancer cell development via mediating H3K18ac through the MDM2-GCN5-SIRT7 axis.

Authors:  Ziming Cheng; Xiufeng Li; Shizhen Hou; Yubing Wu; Yi Sun; Bing Liu
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

7.  Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer.

Authors:  Aubhishek Zaman; Xiaofeng Wu; Andrew Lemoff; Sivaramakrishna Yadavalli; Jeon Lee; Chensu Wang; Jonathan Cooper; Elizabeth A McMillan; Charles Yeaman; Hamid Mirzaei; Michael A White; Trever G Bivona
Journal:  Cell Rep       Date:  2021-08-03       Impact factor: 9.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.